The following items were addressed at the Annual General Meeting of
Diamyd Medical AB (publ) (STO:DIAM.B)(Pink Sheets:DMYDY) held today:
Diamyd Medical's President and CEO Peter Zerhouni gave a retrospective
view of the past year and summarized the most significant events that
took place during the fiscal year and after year-end.
The Company's income statements and balance sheets were adopted and the
Board members and the Chief Executive Officer were discharged from
liability for the 2011/2012 fiscal year. The Annual General Meeting
approved the Board's proposal that no dividend be paid for the 2011/2012
Anders Essen-Möller was re-elected as Chairman of the Board and
Maria-Teresa Essen-Möller was re-elected to the Board. Erik Nerpin and
Jonas Jendi were elected as new Board members. Erik Nerpin, born in
1961, is an attorney and partner at Kilpatrick Townsend in Stockholm.
Jonas Jendi, born in 1970, M.Sc. Economics & Business Administration,
has spent the last 10 years managing the company Cogmed. Cogmed is based
on research from the Karolinska Institute and was acquired by Pearson in
2010. The former Board members Lars Jonsson, Joseph Janes and Christer
Lindberg have declined re-election.
The Annual General Meeting approved the proposed guidelines for
remuneration of the CEO and other senior executives. The Meeting also
approved the proposed remuneration to Board members and the Chairman of
The Annual General Meetng resolved to re-elect the auditing company
Öhrlings PricewaterhouseCoopers until the end of the Annual General
Meeting 2013. Principal auditor is the authorized public accountant Eva
The Annual General Meeting approved the proposed principles for the
appointment of Nomination Committee for the 2013 Annual General Meeting.
The Annual General Meeting resolved to authorize the Board to approve
new share issues for a maximum total of 10 percent of the number of
shares on one or more occasions before the next Annual General Meeting,
and permit the Board to deviate from the shareholders' preferential
rights when so doing. Payment may be made in cash, through a
contribution or by offsetting.
The Annual General Meeting resolved to authorize the Board, for the
period until the next Annual General Meeting, to repurchase series B
shares in Diamyd Medical on Nasdaq OMX Stockholm. The maximum number of
shares repurchased shall be such that Diamyd Medical shares held in
treasury from time to time do not exceed ten percent of all shares in
About Diamyd Medical
Diamyd Medical was founded in 1996 and is active in the field of
pharmaceutical development. Diamyd Medical is headquartered in
Stockholm, Sweden. The Company's development project consists of the
protein GAD65 for the treatment and prevention of autoimmune diabetes. A
Swedish researcher-initiated Phase II study is ongoing to evaluate
whether GAD65 can prevent type 1 diabetes in children who are at high
risk of developing the disease.
Diamyd Medical also has holdings in the gene therapy company Periphagen
Holdings, Inc. (USA), the vaccine company Protein Sciences Corporation
(USA) and the diagnostics company Mercodia AB (Sweden).
Diamyd shares are listed on Nasdaq OMX (segment Small Cap) in Stockholm
(ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by
the Pink OTC Markets and the Bank of New York Mellon (PAL). Further
information is available on the Company's website: www.diamyd.com.
This information is disclosed in accordance with the Swedish Securities
Markets Act, the Swedish Financial Instruments Trading Act, or the
requirements stated in the listing agreements.
Diamyd Medical AB (publ) Karlavägen 108, SE-115 26 Stockholm, Sweden.
Phone: +46 8 661 00 26, Fax: +46 8 661 63 68 E-mail: firstname.lastname@example.org.
Reg. no: 556530-1420
This information was brought to you by Cision http://www.cisionwire.com
[ Back To NFVZone's Homepage ]